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Abstract
Background: The CARTS study is a multicenter feasibility study, investigating the role of rectum saving surgery for
distal rectal cancer.
Methods/Design: Patients with a clinical T1-3 N0 M0 rectal adenocarcinoma below 10 cm from the anal verge will
receive neoadjuvant chemoradiation therapy (25 fractions of 2 Gy with concurrent capecitabine). Transanal
Endoscopic Microsurgery (TEM) will be performed 8 - 10 weeks after the end of the preoperative treatment
depending on the clinical response.
Primary objective is to determine the number of patients with a (near) complete pathological response after
chemoradiation therapy and TEM. Secondary objectives are the local recurrence rate and quality of life after this
combined therapeutic modality. A three-step analysis will be performed after 20, 33 and 55 patients to ensure the
feasibility of this treatment protocol.
Discussion: The CARTS-study is one of the first prospective multicentre trials to investigate the role of a rectum
saving treatment modality using chemoradiation therapy and local excision. The CARTS study is registered at
clinicaltrials.gov (NCT01273051)
Background
Colorectal cancer is the third most common malignancy
in the Netherlands with more than 10.000 new patients
of whom approximately one third have rectal cancer.
Total Mesorectal Excision (TME) using sharp nerve-
sparing dissection, instead of blunt resection, reduced
the 5-year local recurrence rate from up to 45% to less
than 10% in patients with rectal cancer [1,2]. The use of
this nerve-sparing technique results in lower rates of
sexual dysfunction and urinary incontinence, but these
complications are still common after TME [3]. Addition
of preoperative radiotherapy to surgery resulted in a sig-
nificant better local control for resectable rectal cancer.
Five-year local control rate using a short course (5 ×
5 Gy) of pre-operative radiotherapy was 6% compared
to 11% after TME surgery alone [4]. Based on these
results, standard treatment in the Netherlands for T2-3
rectal cancer without threatened circumferential margin
(CRM) or N2 stage is pre-operative short course radio-
therapy followed by TME surgery. Long course chemor-
adiation therapy (CRT) is indicated for locally advanced
disease.
In the majority of patients with rectal cancer a low
anterior resection (LAR) with primary anastomosis will
be performed. These patients have a risk of significant
postoperative morbidity, such as anastomotic leakage,
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faecal (urge) incontinence, tenesmus and soiling. For
patients with distal rectal cancer it is often impossible to
preserve the sphincter and an abdominoperineal resec-
tion (APR) with a permanent colostomy must be per-
formed. Quality of life in these patients was not proven
to be worse than in patients who underwent a LAR [5].
Neoadjuvant chemoradiation therapy
Patients with more advanced tumours are usually treated
with a long course of CRT in order to facilitate tumour
downstaging. Two multicenter randomised trials have
demonstrated the benefit of additional chemotherapy to
radiotherapy, leading to a higher complete response rate
and a lower local recurrence rate after 5 years follow-up
[6,7]. CRT can potentially increase the number of patients
who undergo sphincter sparing surgery, although only few
authors have demonstrated this in a prospective trial
[8-10].
A pathological complete tumour response (pCR) follow-
ing long-course CRT is reported in 8 - 27% of the patients
[10-16]. Patients with a complete response have an
improved overall survival and local recurrences in patients
with ypT0 and ypT1 tumours are low (0% - 6%). The addi-
tional value of TME surgery in case of a pCR after CRT is
questioning. The selection of patients with a pCR is diffi-
cult using imaging techniques and transanal excision of
the remaining tissue or residual tumour is probably the
most profound method.
Local excision/TEM
Transanal local excision (LE) is performed in patients with
benign and low-risk superficial malignant rectal neo-
plasms. Transanal endoscopic microsurgery (TEM) is a
local excision technique which enables the surgeon to per-
form a full thickness excision with great precision. An
operating rectoscope with a diameter of 4 cm and a length
of 12 or 20 cm is used. The scope has four work channels,
a stereo optic vision channel, a light source, and an insuf-
flation port to obtain a pneumorectum for maximum
exposure. TEM is superior to local excision according to
Parks for benign and malignant rectal neoplasms. There is
a significantly lower risk of irradical or incomplete resec-
tion and consequently a lower recurrence rate [17-19].
TEM is also considered an alternative for patients who are
unsuitable for major surgery because of medical comor-
bidity or those patients who require an APR but refuse a
colostomy. Unfortunately, local excision leads to higher
rates of local recurrence and survival may be compro-
mised compared to radical TME surgery except for low-
risk T1 tumours [20,21].
Lymph node involvement
The key to appropriate use of LE for rectal cancer is
patient selection; accurate preoperative primary tumour
staging and prediction of lymph node involvement. For
detection of nodal disease, ERUS and MRI have a similar
sensitivity (67% versus 66%) and specificity (78% versus
76%) [22]. However, both examinations are highly opera-
tor dependent. MRI provides excellent imaging of the
rectum, mesorectum, fascia propria of the rectum, and
other pelvic structures and is useful for determining the
risk of CRM involvement preoperatively. These aspects
are not relevant to early-stage patients considered for
local excision. The risk of lymph node involvement
increases with depth of invasion of the rectal wall. Even
in patients with a T1 stage, there can be lymph node
involvement. The incidence of lymph node metastasis
ranges from 6% to 14% for T1 tumours, 17% to 23% for
T2 tumours, and 49% to 66% for T3 tumours [23]. The
percentage of patients with involved lymph nodes is
much lower after neoadjuvant CRT [24,25], probably
because CRT has sterilised tumour containing lymph
nodes. Others have shown that there is a correlation
between the T stage and the N stage after CRT [26-29].
This effect of neoadjuvant CRT enables a combined
treatment modality with local excision.
Methods/Design
Hypothesis
Since 8% to27% of the patients receiving neoadjuvant CRT
for locally advanced rectal cancer has a pCR [10-15], a rec-
tum saving treatment should be achievable for a number
of patients with distal rectal cancer. In the CARTS-study,
patients will be treated with CRT aiming at reaching a
(near) pCR. By excision of the primary tumour site by
TEM patients with a pathological (near) pCR (ypT0-1) can
be identified.
Objectives
Primary objective of the study is to determine the number
of patients with minimal residual disease (ypT0-1) after
neoadjuvant CRT followed by TEM surgery. The resection
specimen should be complete (> 2 mm margin) without
evidence of nodal metastases (if nodes are found in the
full thickness specimen). Secondary objectives are quality
of life and local recurrence rate.
Design
This study is a non-randomized feasibility study to deter-
mine whether radiotherapy combined with capecitabine
followed by organ-sparing surgery using TEM can be con-
sidered as a valid new treatment modality in distal rectal
cancer. The flow chart of the study is showed in Figure 1.
Study population
Patients who meet the following inclusion criteria are
eligible for participation in this trial: diagnosis of a distal
adenocarcinoma within 10 cm of the anal verge, staged
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as cT1-T3 tumour on imaging, age > 18 years and writ-
ten informed consent.
Exclusion criteria are: Low risk T1, tumour ineligible for
TEM (circular or intra-anal tumour), pre-existing faecal
incontinence (soiling is not), synchronous tumours, or
presence of mesorectal lymph nodes larger than 5 mm on
CT, MRI and/or endorectal ultrasound and contraindica-
tions for capecitabine.
Participating centres
At least 15 Dutch hospitals will participate in this study,
including 3 university medical centers.
Interventions
Neoadjuvant chemoradiation therapy
All patients will receive neoadjuvant CRT, consisting of
radiotherapy with a total dose of 50 Gy which is given in
25 fractions during 5 weeks. Patients will receive 825 mg/
m2 capecitabine b.i.d. 7 days per week during the whole
treatment period. Six weeks after ending the CRT, ther-
apy effect is evaluated by MRI, rectoscopy and ERUS.
Patients with a clinical T0-2 tumour after CRT will
undergo LE using TEM 8 - 10 weeks after the end of the
neoadjuvant treatment. All other patients will undergo
TME surgery.
After histological examination of the resected specimen,
all patients with an ypT2-3 tumour, positive resection
margins, or lymphangioinvasive growth, will undergo radi-
cal surgery within 4-6 weeks after the TEM-procedure.
TEM
TEM will be performed as described by Buess [30].
Under general/spinal anesthesia, a specialized TEM rec-
toscope of 12 or 20 cm in length (Wolf GmbH Knittlin-
gen or Storz GmbH Tuttlingen, Germany) is inserted
T1-T3 N0M0 
distal rectal carcinoma
neoadjuvant chemoradiation
 (25x2Gy with Capecitabine)
No clinical response
(>cT2 tumour) six weeks after 
CRT
Good clinical response
(scar or ulcus, cT0-T2 tumor) six 
weeks after CRT
TEM
8-10 weeks after CRT
TME
8-10 weeks after CRT
ypT0/ypT1
Histological
Analysis
> ypT1
Follow-up TMEBefore 14 weeks after CRT
Follow-up
Figure 1 flowchart of the CARTS-study.
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within the rectum to assure proper visualization of the
lesion. The rectal cavity is insufflated with CO2 by a
combined endosurgical unit to achieve constant disten-
sion for appropriate visualization of the rectal neoplasm.
The combined endosurgical unit further regulates irriga-
tion and suction, thereby maintaining a constant intrar-
ectal pressure.
Outcome parameters
Primary outcome
Primary objective of the study is to demonstrate that
more than 12 of 55 patients have minimal residual dis-
ease 8 - 10 weeks after neoadjuvant CRT. Minimal resi-
dual disease is defined as an ypT0 or ypT1 stage.
Secondary outcome
Secondary objectives are local recurrence rate (LRR) and
quality of life after the given treatment. All participating
patients will have intensive follow-up during three years to
evaluate the presence of locoregional and distal recurrent
disease. Patients will be evaluated at the outpatient clinic
every three months and MRI of the pelvis and CT scan of
the thorax and abdomen are performed every six months.
Patients who have been successfully treated with TEM will
be followed with rectoscopy and ERUS every three
months. Quality of life will be measured with the EORTC-
QLQ-C30 and the EORTC-QLQ-C38 before CRT and
four times during follow-up.
The following issues will also be registered and analysed
for both the patients who undergo TEM and those under-
going TME: treatment related toxicity of the preoperative
CRT and postoperative complications. The number of
positive lymph nodes in TME patients will be assessed.
This will give valuable information on the preoperative
imaging modalities. All patients will be asked to consent
with storage of tumour biopsies for translational research.
Sample size calculation
Fifty-five patients will be included in this study. The study
treatment protocol is considered successful if 30% or more
of the included patients will complete CRT and undergo
TEM surgery with complete resection of the ypT0-1
tumour. This means a resection with > 2 mm resection
margin. A response of 15% or less will be considered a fail-
ure of this treatment modality. A three-step model for
phase II cancer clinical trials will be used for calculating
patient numbers with an alpha and beta of 0.1. An evalua-
tion will be planned after 20 and 33 patients.
Ethics
The medical ethical committee of the Radboud Univer-
sity Nijmegen Medical Centre has approved the study
protocol (NL 2882.091.10). The CARTS study is regis-
tered at clinicaltrials.gov (NCT01273051)
Prior to registration written informed consent will be
obtained in all patients.
Discussion
During the last decade, the introduction of TME-surgery
and neoadjuvant treatment strategies has led to an
improved overall and disease free survival in patients
with rectal cancer [31-34]. With this improvement of
oncological outcome, the question has risen if new
treatment modalities can be developed with less morbid-
ity and mortality and an increase in quality of life.
Local excision via TEM of rectal tumours has demon-
strated to be a technique with significantly lower morbid-
ity and mortality rates and hospital stay compared to
standard TME surgery [21,35]. Recently, Doornebosch et
al. demonstrated that functional outcome was also better
after TEM in comparison with TME. However, TEM as a
solitary procedure is not considered an oncological save
treatment. Even in T1tumours, local recurrences are
reported in 6-18% of the patients [20]. For T2 or T3 carci-
nomas, local recurrence rates are unacceptable high
[36-38] and LE is only performed in such patients if they
are physically unfit to undergo standard rectal surgery
[39]. Therefore, alternative strategies should be accounted
for in order to improve the oncological results after LE
(TEM). Postoperative radiotherapy or CRT has been used
in several centers after TEM for rectal cancer, but did not
lead to acceptable results [38,40]. Neoadjuvant treatment
with CRT is another strategy which is already generally
used in locally advanced rectal carcinomas with acceptable
toxicity [10,41].
After CRT, pCR has been reported in 8-27% of the
patients [10-15]. This has led to evaluation of a wait and
see strategy for patients with a clinical complete response
(cCR), which is currently investigated for oncological
safety by several investigators [42]. However, a pathologi-
cal evaluation of the tumour remnant has several potential
advantages to select patients for rectum sparing treatment.
First of all, cCR is not always a pCR [42-45]. We have
described a patient with a cCR, which demonstrated to be
an ypT2 tumour after TEM, but eventually turned out to
be a ypT3N1 tumour after TME surgery [45]. In these
patients who seem to have a favourable response, a wait
and see policy will delay adequate mesorectal excision.
Secondly, a clinical partial response can be a pCR. In
order to prevent patients with palpable tumour scarring
from undergoing TME surgery, a biopsy of the scar seems
to be the best option. Thirdly, patients with a near com-
plete response after CRT (ypT1) can be adequately treated
with a full thickness excision of the rectal wall.
The combination of TEM and CRT has been studied
retrospective [46] and is studied in a similar protocol in
the USA (ACOSOG Z0641 study) [47]. Local recurrence
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after a pCR (ypT0) has never been described, and also
the local recurrence rate after a near complete response
(ypT1) is reported to be low (0-6%). For ypT2 carcino-
mas, varying LRR have been described but are likely to
be above 10% [46]. Despite these observations the ACO-
SOG Z0641 protocol prescribes a wait and see policy
for ypT2 tumours [48]. We feel that this might not be
an oncological save treatment and have therefore chosen
to perform TME surgery in all patients with ypT2 and
higher tumours and monitor long term outcome.
Another interesting observation will be the registration
of complications after TEM. In the case reports
described in the literature, several patients experienced
wound complications, but the exact rate will be estab-
lished in this prospective analysis [49].
The trial accrual is expected to be adequate in the
above mentioned centers and it is assumed that in two
years all patients will be treated. This trial will give us
an answer if this multimodality protocol for rectum sav-
ing treatment of rectal cancer is feasible and if so, a ran-
domized phase III trial will be conducted.
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